Figure 6.

Role of IFN-γ and TRAIL in antimetastatic effect of α-GalCer. Groups of five IFN-γ^−/− or pfp^−/− mice were inoculated (A) intrasplenically with 3 × 10⁵ Renca tumor cells or (B) intravenously with 1 × 10⁵ Renca tumor cells on day 0. As indicated, some groups of mice were treated with: 2 μg α-GalCer (α-GC) intraperitoneally on days 0, 4, and 8 and/or 0.25 mg anti-TRAIL mAb on days 0, 1, and 7. The (A) livers and (B) lungs were removed from mice on day 14, and the metastatic nodules quantified. Data are recorded as the mean ± SE, with the signi-ficance of anti-TRAIL mAb-treated mice compared with mice treated with α-GalCer alone as defined by *P < 0.05, **P < 0.01, Mann-Whitney U test. Control IgG was without effect in pfp^−/− or IFN-γ^−/− mice (data not shown). α-GalCer was statistically effective alone compared with no treatment in the livers and lungs of pfp^−/− mice (P < 0.01).